Supplement Market Pulse

FDA sent letters to manufacturers reinstating NMN's status as a legal dietary ingredient, reversing its 2022 determination that NMN was excluded under the drug-preclusion clause. The agency concluded NMN was marketed as a supplement before it was authorized for drug investigation. Companies still need a New Dietary Ingredient Notification on file unless sourcing from a supplier that already filed one.

FDA published a letter to industry on December 11, 2025 signaling intent to amend the rule requiring the DSHEA disclaimer on every label panel where a 403(r)(6) claim appears, and is exercising enforcement discretion in the interim. CRN has petitioned FDA to confirm a single, centralized disclaimer linked by asterisk is sufficient.

Xlear sued the FTC after the agency dropped its 2021 case over the company's sinus rinse marketing, asking a court to bar FTC from requiring clinical-trial-level substantiation for health claims and to shift the burden onto government to disprove claims instead. The Alliance for Natural Health filed a parallel petition seeking withdrawal of FTC's 2022 substantiation guidance. The suit is framed to test the Loper Bright precedent.

FDA and CDC traced the outbreak to contaminated moringa leaf powder supplied to multiple brands. The case now totals 119 illnesses and 32 hospitalizations across 36 states since August 2025. FDA had declared the outbreak over on March 17, 2026, but reopened the investigation after additional cases surfaced in late June.

The CONCRET-MENOPA randomized controlled trial and related studies found creatine HCl and ethyl ester supplementation improved cognition, strength, sleep quality, and body composition in perimenopausal and menopausal women over 8 to 14 weeks. Researchers note creatine's relevance ties to declining estrogen forcing the brain to adapt to a different energy environment.